Supernus Pharmaceuticals, Inc. (SUPN)
NASDAQ: SUPN · IEX Real-Time Price · USD
34.09
+0.35 (1.04%)
Mar 28, 2024, 3:59 PM EDT - Market closed
Supernus Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Year | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 - 2009 |
---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 607.52 | 667.24 | 579.78 | 520.4 | 392.76 | 408.9 | 302.24 | 215 | 147.47 | 92.68 | Upgrade
|
Revenue Growth (YoY) | -8.95% | 15.09% | 11.41% | 32.50% | -3.95% | 35.29% | 40.57% | 45.80% | 59.12% | 671.10% | Upgrade
|
Cost of Revenue | 83.78 | 87.22 | 75.06 | 52.46 | 16.66 | 15.36 | 15.22 | 11.99 | 8.42 | 5.76 | Upgrade
|
Gross Profit | 523.74 | 580.02 | 504.71 | 467.94 | 376.1 | 393.54 | 287.02 | 203.02 | 139.04 | 86.92 | Upgrade
|
Selling, General & Admin | 336.36 | 377.22 | 304.76 | 200.68 | 153.25 | 154.7 | 137.91 | 106.01 | 89.06 | 72.61 | Upgrade
|
Research & Development | 91.59 | 74.55 | 90.47 | 75.96 | 69.1 | 89.21 | 49.58 | 42.79 | 29.14 | 19.59 | Upgrade
|
Other Operating Expenses | 102.57 | 82.63 | 29.99 | 17.6 | 5.18 | 5.19 | 0 | 0 | 0 | 0 | Upgrade
|
Operating Expenses | 530.53 | 534.4 | 425.22 | 294.24 | 227.52 | 249.1 | 187.48 | 148.8 | 118.2 | 92.2 | Upgrade
|
Operating Income | -6.79 | 45.61 | 79.5 | 173.7 | 148.57 | 144.44 | 99.54 | 54.22 | 20.84 | -5.28 | Upgrade
|
Interest Expense / Income | 2.42 | 7.07 | 23.42 | 23.75 | 22.71 | 18.11 | 1.57 | 5.09 | 4.77 | 5.62 | Upgrade
|
Other Expense / Income | -11.97 | -22.2 | -17.1 | -18.7 | -21.62 | -13.84 | -2.65 | -1.24 | 1.46 | -0.6 | Upgrade
|
Pretax Income | 2.77 | 60.74 | 73.18 | 168.65 | 147.49 | 140.18 | 100.62 | 50.37 | 14.61 | -10.3 | Upgrade
|
Income Tax | 1.45 | 0.03 | 19.75 | 41.7 | 34.43 | 29.18 | 43.33 | -40.85 | 0.67 | 0.63 | Upgrade
|
Net Income | 1.32 | 60.71 | 53.42 | 126.95 | 113.06 | 110.99 | 57.28 | 91.22 | 13.94 | -10.93 | Upgrade
|
Net Income Growth | -97.83% | 13.64% | -57.92% | 12.29% | 1.86% | 93.76% | -37.20% | 554.20% | - | - | Upgrade
|
Shares Outstanding (Basic) | 55 | 54 | 53 | 53 | 52 | 52 | 51 | 49 | 47 | 42 | Upgrade
|
Shares Outstanding (Diluted) | 56 | 62 | 54 | 54 | 54 | 54 | 53 | 52 | 51 | 42 | Upgrade
|
Shares Change | -10.01% | 13.47% | 1.24% | -0.24% | -0.52% | 1.50% | 3.08% | 1.07% | 21.06% | 32.69% | Upgrade
|
EPS (Basic) | 0.02 | 1.13 | 1.01 | 2.41 | 2.16 | 2.13 | 1.13 | 1.84 | 0.29 | -0.26 | Upgrade
|
EPS (Diluted) | 0.02 | 1.04 | 0.98 | 2.36 | 2.10 | 2.05 | 1.08 | 1.76 | 0.28 | -0.26 | Upgrade
|
EPS Growth | -98.08% | 6.12% | -58.47% | 12.38% | 2.44% | 89.81% | -38.64% | 528.57% | - | - | Upgrade
|
Free Cash Flow | 110.53 | 116.41 | 125.08 | 134.71 | 141.74 | 128.14 | 112.61 | 65.21 | 32.42 | -25.09 | Upgrade
|
Free Cash Flow Per Share | 2.03 | 2.17 | 2.36 | 2.56 | 2.70 | 2.46 | 2.22 | 1.32 | 0.68 | -0.59 | Upgrade
|
Gross Margin | 86.21% | 86.93% | 87.05% | 89.92% | 95.76% | 96.24% | 94.97% | 94.43% | 94.29% | 93.79% | Upgrade
|
Operating Margin | -1.12% | 6.84% | 13.71% | 33.38% | 37.83% | 35.33% | 32.93% | 25.22% | 14.13% | -5.69% | Upgrade
|
Profit Margin | 0.22% | 9.10% | 9.21% | 24.39% | 28.79% | 27.14% | 18.95% | 42.43% | 9.46% | -11.79% | Upgrade
|
Free Cash Flow Margin | 18.19% | 17.45% | 21.57% | 25.89% | 36.09% | 31.34% | 37.26% | 30.33% | 21.98% | -27.07% | Upgrade
|
Effective Tax Rate | 52.47% | 0.05% | 26.99% | 24.72% | 23.35% | 20.82% | 43.07% | -81.11% | 4.56% | - | Upgrade
|
EBITDA | 90.04 | 153.36 | 129.19 | 210.54 | 176.85 | 165.35 | 110.32 | 57.86 | 20.3 | -3.75 | Upgrade
|
EBITDA Margin | 14.82% | 22.98% | 22.28% | 40.46% | 45.03% | 40.44% | 36.50% | 26.91% | 13.77% | -4.04% | Upgrade
|
Depreciation & Amortization | 84.86 | 85.54 | 32.6 | 18.14 | 6.66 | 7.06 | 8.13 | 2.4 | 0.92 | 0.93 | Upgrade
|
EBIT | 5.18 | 67.81 | 96.6 | 192.4 | 170.19 | 158.29 | 102.19 | 55.46 | 19.38 | -4.67 | Upgrade
|
EBIT Margin | 0.85% | 10.16% | 16.66% | 36.97% | 43.33% | 38.71% | 33.81% | 25.79% | 13.14% | -5.04% | Upgrade
|